Treatment of newly diagnosed multiple myeloma in transplant-eligible patients
Recent advances in novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have markedly improved treatment outcomes in patients with multiple myeloma. The novel agent-based induction, followed by autologous transplantation, is considered as the standard treatment for transplant-eligible patients. Post-transplant consolidation and maintenance therapy can help maintain the subsequent response and further improve the treatment outcome in patients. Currently, there are several validated sensitive assays evaluating minimal residual disease (MRD), which have provided a means to quantitatively assess residual disease and accurately predict its prognosis in terms of progression-free and overall survival. Novel clinical studies that formally assess the effect of MRD negativity on clinical decision-making are ongoing. This session aims to provide an in-depth and comprehensive summary of the latest treatment strategy and MRD-based knowledge in newly diagnosed transplant-eligible patients with multiple myeloma.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
---|---|
Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 61(2020), 9 vom: 25., Seite 1306-1316 |
Sprache: |
Japanisch |
---|
Beteiligte Personen: |
Sakaida, Emiko [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 18.01.2021 Date Revised 18.01.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.11406/rinketsu.61.1306 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317303031 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317303031 | ||
003 | DE-627 | ||
005 | 20231225163000.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||jpn c | ||
024 | 7 | |a 10.11406/rinketsu.61.1306 |2 doi | |
028 | 5 | 2 | |a pubmed24n1057.xml |
035 | |a (DE-627)NLM317303031 | ||
035 | |a (NLM)33162530 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a jpn | ||
100 | 1 | |a Sakaida, Emiko |e verfasserin |4 aut | |
245 | 1 | 0 | |a Treatment of newly diagnosed multiple myeloma in transplant-eligible patients |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.01.2021 | ||
500 | |a Date Revised 18.01.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Recent advances in novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have markedly improved treatment outcomes in patients with multiple myeloma. The novel agent-based induction, followed by autologous transplantation, is considered as the standard treatment for transplant-eligible patients. Post-transplant consolidation and maintenance therapy can help maintain the subsequent response and further improve the treatment outcome in patients. Currently, there are several validated sensitive assays evaluating minimal residual disease (MRD), which have provided a means to quantitatively assess residual disease and accurately predict its prognosis in terms of progression-free and overall survival. Novel clinical studies that formally assess the effect of MRD negativity on clinical decision-making are ongoing. This session aims to provide an in-depth and comprehensive summary of the latest treatment strategy and MRD-based knowledge in newly diagnosed transplant-eligible patients with multiple myeloma | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a High dose melphalan | |
650 | 4 | |a MRD | |
650 | 4 | |a Maintenance treatment | |
650 | 4 | |a Transplant-eligible myeloma | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Proteasome Inhibitors |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 61(2020), 9 vom: 25., Seite 1306-1316 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
773 | 1 | 8 | |g volume:61 |g year:2020 |g number:9 |g day:25 |g pages:1306-1316 |
856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.61.1306 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 61 |j 2020 |e 9 |b 25 |h 1306-1316 |